BIG PHARMA EARNINGS WATCH: ROCHE

Roche Continues Hiking Prices on Blockbuster Drugs While Beating Wall Street Expectations

Last week, Big Pharma giant Roche reported Q2 earnings that beat Wall Street analysts’ expectations as they hiked the price of more than 30 prescription drugs in their portfolio so far this year.

Roche, like many of its Big Pharma peers, has consistently beat Wall Street analysts’ revenue expectations, including in 2021, 2022, 2023 and 2024, while continuing to engage in anti-competitive practices and hike prices on blockbuster drugs in its portfolio.

Get the full recap on Roche’s earnings here:

• Roche saw Q2 earnings that beat Wall Street analysts’ expectations.
• The Big Pharma giant’s operating profit was up six percent at $15.15 billion for Q2.
• The company’s breast cancer drug, Phesgo, jumped 55 percent to $1.5 billion, while asthma treatment Xolair grew 34 percent to $1.8 billion.

Roche’s Q2 earnings follow their continued practice of price hikes and anti-competitive practices on their blockbuster drugs.

• As its sales have climbed, Roche has repeatedly hiked prices on prescription products in its portfolio. Roche has increased prices on 33 prescription drugs thus far in 2025, including multiple sclerosis drug Ocrevus by 4.7 percent, macular degeneration drug Vabysmo by 2.5 percent and asthma treatment Xolair by 3.1 percent.
• Last year, the Big Pharma company increased prices on 35 prescription drugs.
• In 2023, Roche increased prices on at least 22 prescription drugs in its portfolio.
• A report released in late 2019 found that Roche’s price hikes on the popular rheumatoid arthritis drug Rituxan were not supported by innovation or improvements and cost U.S. taxpayers $806 million.

Stay tuned as we continue to monitor second quarter earnings calls from brand name drug companies in the coming weeks.

Read more on Q2 earnings from Johnson & Johnson HERE.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.